We have in our recent studies employed an integrated approach to understand breast cancer heterogeneity by modeling mRNA, CNAs (copy number alterations), miRNAs, and DNA methylation in a pathway context using Paradigm (Pathway Recognition Algorithm using Data integration on Genomic Models). We demonstrate that combining mRNA expression and DNA copy number provide the best predictive value with respect to patient prognosis and identify key molecular and stromal signatures. A chronic inflammatory signature, which promotes the development and/or progression of various epithelial tumors. By development of these new analytic methods, we get closer to the target of understanding of the molecular pathways before and under development of tumors. We get a bigger cytokines’ profile picture during and after treatment, which would help to fight the cancer treatment related symptoms and fatigue. We aim at getting a better understanding of the disease, which can us help finding out target proteins for treatment of the tumors. The research is divided in two groups; The Genome Variation (Oslo University Hospital) and Oncogenomics (EpiGen, Akershus University Hospital). 

Group leader Vessela Kristensen, PhD, professor, Akershus University Hospital and Oslo University Hospital.

Group members, OUS:

• Thomas Fleischer, Ph.D.
• Jovana Klajic, Ph.D.
• Miriam Ragle Aure, Ph.D.
• Sunniva Stordal Bjørklund, Ph.D.
• Evita Lindholm, Ph.D.
• Xavier Tekpli, Ph.D.
• Mev Domingues Valentin, Ph.D.
• Marie Elise Engkvist, M.Sc.
• Marie Fongaard, M.Sc.
• Grethe Irene Grenaker Alnæs, M.Sc.
• Jørgen Ankill, B.Sc.
• Katrine Bølstad, B.Sc.